iTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2018 L.P. Mpm Sells 630,191 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the transaction, the insider now owns 2,108,594 shares of the company’s stock, valued at $16,995,267.64. The trade was a 23.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

iTeos Therapeutics Stock Up 4.9%

ITOS stock opened at $7.97 on Friday. The firm has a market cap of $305.04 million, a price-to-earnings ratio of -2.53 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.70. The company’s fifty day simple moving average is $6.59 and its 200 day simple moving average is $7.42.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. Research analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares in the last quarter. Wells Fargo & Company MN grew its position in iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after purchasing an additional 2,402 shares in the last quarter. Virtus ETF Advisers LLC grew its position in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after purchasing an additional 3,293 shares in the last quarter. Empowered Funds LLC grew its position in iTeos Therapeutics by 5.0% in the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after purchasing an additional 3,305 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its position in iTeos Therapeutics by 5.0% in the 4th quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company’s stock worth $530,000 after purchasing an additional 3,305 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

Analyst Ratings Changes

ITOS has been the subject of several recent analyst reports. Leerink Partnrs downgraded shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $15.00 to $8.00 in a research note on Tuesday. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Leerink Partners reiterated a “market perform” rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday. Finally, HC Wainwright downgraded shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, iTeos Therapeutics has an average rating of “Hold” and a consensus price target of $17.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.